Welcome back to Higher Law, our weekly briefing on all things cannabis. I'm Cheryl Miller, reporting for Law.com from Sacramento. It's the day you've been waiting for. Happy Lima Bean Respect Day.

This week we're looking at:

  • The FTC, Congress, the FDA & CBD.
  • What Realtors say about cannabis properties.
  • A kratom class action.
  • The latest congressional cannabis bills.

Thanks as always for reading. Got a story idea or feedback? You can send it all to me at [email protected]. You can also call me at 916.448.2935. Follow me on Twitter: @capitalaccounts

U.S. Federal Trade Commission building in Washington, D.C. Photo: Diego M. Radzinschi/ALM U.S. Federal Trade Commission building in Washington, D.C. Photo: Diego M. Radzinschi/ALM

The FTC, the FDA, Congress and CBD: Warning Letters Abound

Federal regulators' nebulous oversight relationship with cannabis and CBD was highlighted once again over the last week in two distinct actions.

Last Friday, the Federal Trade Commission publicly warned almost 700 companies not to make unsubstantiated health claims about its products or to use misleading endorsements. The 16-page list of "warned" pharmaceutical and dietary supplement companies included at least a half-dozen CBD purveyors, including Canopy Growth USA, Charlotte's Web Inc. and Medterra CBD.